Buying shares?

I agree with Branson when he says the stock market prices are a largely irrelevant absolute number, and other factors (employment, productivity, growth) are more important.

If your house is 'worth' £200k in the market today and only worth £150k tomorrow, this should not affect anything unless you are looking to sell.
 
KOOV

Waheed Alli, Chairman of Koovs, said:

"It has been another period of exceptional sales growth for KOOVS.COM, as young, fashion forward Indians continue to take Koovs to their hearts in increasing numbers. We have a clear strategy and fundraising plan to scale the business and deliver continued growth. I am delighted to welcome Mary Turner, our new CEO, to the business who brings exceptional experience, energy and enthusiasm to our team."

Mary Turner, CEO, said:

"It is an incredibly exciting time to join Koovs, as young, fashion-conscious Indians are searching for brands that share their passion for exclusive western fashion. I have always described Koovs as India's best kept secret and I am delighted to be part of the journey as we build our profile and ensure more young customers can share this secret."


This IPO'd just over a year ago at c.200p and was promoted as the next ASOS for India with some of the Management I think having been early part of ASOS success story. Shows just how hard it is for even experienced Management teams to deliver similar business models in new unfamiliar territories.

p.php
 
This guy has a following amongst gold bugs

Saying stockmarkets in correction mode since Fed rate hike, real economy could go into recession(if not in recession already), reckons Fed will have to capitulate and do about turn and reduce rates even taking them negative (QE4)

<iframe width="560" height="315" src="https://www.youtube.com/embed/Jdf5zsko4Wo" frameborder="0" allowfullscreen></iframe>
 
Gold

au2920lf_ma.gif


Doesn't look like a big or solid enough basing pattern to me, although $1000 could act as major support and the 'bear' phase now looks to have mirrored the 'bull' phase in terms of time if not magnitude
 
Last edited:
All my stocks going downhill. Market is very volatile, especially Asian market. Dow and Nasdaq is not promising either. Very tough times ahead as a trader :(

Sent from my GT-I9505 using Tapatalk
 
Interesting insider view from a Convertible owner in an AIM small cap stock :-

One of the major backers of PeerTV from the start has been investment firm CSS. In its latest newsletter it writes about PeerTV and Digitek - the company Peer is heavily invested in. CSS states:

It is painful to have to write about these two companies. Both companies have failed to achieve the potential of their markets. Being on the AIM market the companies have succeeded in financing themselves but at the cost of an almost total erosion of original shareholder value. Digitek is currently seeking to restructure its loan notes and to attempt a new start, but there is no certainty ofthe survival of this company.

The lessons to be learned from this experience are that the AIM market is brutal on share values when companies need recurring access to capital. AIM does supply the capital but at ever diminishing share prices. The second lesson we have learned is that restructuring of debt instruments with multiple investors simply does not progress the way an institutional restructuring with more experienced investors might do so. We hope we are all wiser for these experiences.


- See more at: http://www.shareprophets.com/views/...d-ramp-this-is-a-mockery#sthash.TJUnqMIK.dpuf
 
OXP

Is £67m Market Cap too cheap for a Company targeting this market opportunity ?


Ready to enter partnering discussions on key OXPzeroTM NSAIDs


Oxford Pharmascience, the Company that redevelops medicines to make them better, safer and easier to take, today announces that it has finalised commercial materials to allow the Company to enter partnering discussions for both its OXPzeroTM Ibuprofen and OXPzeroTM Naproxen assets.

The Company reported in November 2015 that it was in the final stages of completing preparation of these commercial discussion materials for the OXPzeroTM Ibuprofen platform. This task has now been completed and, with further technical progress made in recent months across the wider platform, the Board is now pursuing opportunities for commercialisation of both its lead OXPzeroTM Ibuprofen asset and OXPzeroTM Naproxen. Ibuprofen and naproxen are the two dominant NSAID molecules in the pain relief and anti-inflammatory sector, with combined worldwide sales in excess of $5bn per annum.(1)
 
Maybe a good time to buy producing small gold miners ?

Benefit from higher Gold price and lower oil price.
Other producers/explorers/developers unlikely to be able to get finance for expansionary capex thus reducing supply.
Small miners with cashflow can buy up decent projects for future building up potential reserve/resource

Some I'm keeping an eye on

POG, AAM, ASA
 
ASA could be interesting. Formerly MWA. They have a cash generating gold mine but a cash burning nickel side. The cash burning nickel side is funding a good strategic asset so Management seem wedded to it but if they mothballed it the rest of the Company looks very cheap.

http://www.investegate.co.uk/asa-resource-grp-plc--asa-/rns/half-yearly-report/201512111619218570I/

Mkt Cap c.$8m
Net Tangible Asset Value looks c.$50m
Gold mine produced $6m EBITDA in the last reported 6m period

Screenshot 2016-01-27 at 2.42.52 AM.jpg

There is quite a bit of debt but should be serviceable so EV/EBITDA probably not outlandish maybe 2-3x ?
 
Last edited:
CPX - looks to be building up again - Half year report should be published first week of Feb.
 
CPX - fingers crossed. Lost faith in Management but think the tech is good enough to pull them out. They wouldn't have Murata as a partner otherwise. They've spent $100m on it. Had major investment along the way from Intel and Murata. Australian Govt putting in about $1-2m a year to support the R&D.

This is worth £50m+ if they ever start selling the stuff.
 
HNR

<iframe width="560" height="315" src="https://www.youtube.com/embed/yVt9gHbL3Wk" frameborder="0" allowfullscreen></iframe>
 
Maybe a good time to buy producing small gold miners ?

Benefit from higher Gold price and lower oil price.
Other producers/explorers/developers unlikely to be able to get finance for expansionary capex thus reducing supply.
Small miners with cashflow can buy up decent projects for future building up potential reserve/resource

Some I'm keeping an eye on

POG, AAM, ASA

The AAM I mentioned is called Anglo Asian Mining but ticker code is actually AAZ

p.php


Had a couple of good days. I don't feel that comfortable with it as it is based in a former Stan country and owes a lot of debt which means shareholders are in danger of total wipeout if debt isn't serviced for whatever reason. Oftentimes with debt, the covenants are unknown and thus you can get blindsided owning the 'stub equity'.
 
PVCS

Disappointment being expressed by some re no news on cash / short term profits / liquidiation value realisation.

However bigger story is that the Net Tangible Asset Value of the Operating Assets which by now should have been written down to the max in the accounts, should surely start to be written back up if the Company's operating assets are now cashflow positive again ?

I guess market may still want reassurance on sustainability and longevity of that cashflow positivity and it is unlikely to be reflected in asset value write-ups until historic accounts for H1 2016 in Sept/Oct 2016 ?

How quickly will market start to discount what looks like a real value opportunity ?

Market pricing PVCS at £12m (8p per share)

When the Book Value (very historic Aug 2015 for H1 2015) looks to be a multiple of that (and that is before any potential asset revaluation/write ups)

Screenshot 2016-02-10 at 9.40.35 AM.jpg

Note very little of the Asset Value is 'Intangibles'.
 
My analogy to AFPO was that I thought it had potential given optionality and chart but didn't actually invest !
 
My analogy to AFPO was that I thought it had potential given optionality and chart but didn't actually invest !

Perhaps, stick a post-it note or something on your desktop. That way you'll remember to buy this time 😂
 
Having said that the chart looks to have based, if Lenigas is true to form will use the good news to ramp prior to placing so might be due a run

big.chart
 
Hard to know because CPX even after their recent presentations there is very little real evidence of their partnerships producing results let alone commercial success. Frustrating.
 
http://www.investegate.co.uk/dagang...ntention-to-float-on-aim/201602220700116664P/

The Group operates DagangHalal.com, the world's first global e-marketplace to provide Halal verification. With its unique Halal Verified Engine ("HVE") database, DagangHalal.com allows the rapidly growing community of Halal suppliers and consumers to deal with confidence, assuring them that the products and services being purchased are Halal.

Halal is a religion-driven concept, which is implemented in adherence to the core principles and values, laid down by the Islamic principles of Shari'ah law so that a product is suitable for consumption by a Muslim. Halal is applicable across a range of industries, including food and beverages, consumer goods and personal care, healthcare and pharmaceuticals, science and new technologies and hospitality and leisure amongst others.

Globally, the Halal industry is highly fragmented being composed of small and medium enterprises. The global Halal market is one of the fastest growing markets in the world with the Muslim population expected to grow from 1.6 billion in 2010 to 1.8 billion in 2020.

Over the past three financial years the Group's revenue has increased from MYR1.18 million for the financial year ended 31 December 2012 to MYR3.405 million for the financial year ended 31 December 2014, representing an increase over the period of 187%.
 
This Biotech Capital Conference looks an interesting event in London on Thursday 3rd March

I think Angle (AGL) and Scancell (SCLP) particularly interesting

https://www.eventbrite.co.uk/e/biotech-capital-conference-tickets-21514598744

We are delighted to bring you the Biotech Capital Conferences.

These institutionally focussed daytime events will be held at the Brewery, Chiswell Street, in the heart of the city.
The events are aimed at biotech investors, investment managers, private client brokers and analysts who want exclusive access to the management of some of the market's most interesting, high growth biotech companies.
You can find out more about Biotech Capital by visiting www.biotech-capital.com.
Joining us for this event will be Midatech Pharma (LON:MTPH), ANGLE (LON:AGL), C4X Discovery (LON:C4XD), Tissue Regenix (LON:TRX), Abzena (LON:DEMG), Scancell (LON:ABZA) & Rex Bionics (LON: REXB).
Last year was huge for Midatech, which boosted its presence in the US with the £19.5mln acquisition of DARA Biosciences. The company is into the hot area of nano-medicine and is advancing a pipeline of novel clinical and pre-clinical product candidates.
When our joints begin to ache and our parts begin to break, Tissue Regenix the company we’ll all rely. For it produces tendons and ligaments around the knee-cap that will keep us mobile in old age. This is a huge market that traditional medical equipment groups are only just tapping into.
Strictly speaking not life sciences, Rex Bionics does offer a revolution in healthcare. Its robotic legs have allowed severely disabled users to walk and have turned on its head the rehabilitation process for some patients with robot assisted physiotherapy.
Its last update Horizon Discovery revealed it was firing on all cylinders. It is revenue generating thanks to its contract research arm, but is also exposed to the upside to drug discovery process. In fact it could be due milestone payments of more than £200mln for the work it is carried out refining and optimising treatments.
Abezena, a little like Horizon, helps drug companies produce better drugs. A huge tick in the box recently came from an unnamed but major biotech, which will use Abzena’s ThioBridge platform to design more effective anti-body based treatments. The deal could be worth as much as US$150mln over time.
Scancell Holdings has delivered some very impressive results tackling hard to treat cases of melanoma using its lead drug SCIB 1. The company is a leader in the field of immuno-oncology, which uses the body’s own immune system to kill cancer.
Last, but certainly not least is C4X Discovery, which is pioneering what it hopes will be an effective treatment for the skin condition psoriasis. If it successfully finds a cure, then it will have also uncovered the keys for a market worth US$6bn annually.
Presentations will be split by a coffee break and followed by a complimentary buffet lunch, giving you the opportunity to speak with the directors and other investors.
Please arrive by 9:00 to allow time for registration and to ensure that you secure a seat.
WHEN
Thursday, 3 March 2016 from 08:30 to 14:30 (GMT) - Add to Calendar
WHERE
The Brewery - 52 Chiswell Street London, Greater London EC1Y 4SA GB - View Map
 
CPX break the moving average resistance on volume and this could go nutty

people realising a £5m cap is far too low for a company with so much potential

big.chart

CPX chart starting to look more constructive. Would like to see it back above 200 day EMA / 4p+

Medium term downtrend looks like it may have been broken at least
 
CPX chart starting to look more constructive. Would like to see it back above 200 day EMA / 4p+

Medium term downtrend looks like it may have been broken at least


The way I see it, when employees opted to take share than wages at 6.23 per share, they would at least expect to double that
 
I do think employees think long term and see the value so expect they will eventually make the $100m invested in this yield dividends for shareholders
 
I do think employees think long term and see the value so expect they will eventually make the $100m invested in this yield dividends for shareholders[/QUOTE

s28, forget CPX for a min did you check your trading accounts and ensure you are in AFPO this time round 🚀
 
CPX no particular news it seems but stock trying to break out above 200 day MA today having already broken the medium term downtrend as identified last week.
 
ASA could be interesting. Formerly MWA. They have a cash generating gold mine but a cash burning nickel side. The cash burning nickel side is funding a good strategic asset so Management seem wedded to it but if they mothballed it the rest of the Company looks very cheap.

http://www.investegate.co.uk/asa-resource-grp-plc--asa-/rns/half-yearly-report/201512111619218570I/

Mkt Cap c.$8m
Net Tangible Asset Value looks c.$50m
Gold mine produced $6m EBITDA in the last reported 6m period

View attachment 63917

There is quite a bit of debt but should be serviceable so EV/EBITDA probably not outlandish maybe 2-3x ?

Some historic figures
 
AFPO interesting chart set up. Simply don't trust the guy now though. Flattered to deceive since initial euphoria.
 
<blockquote class="twitter-tweet" data-lang="en-gb"><p lang="en" dir="ltr">i am excited that the takeover of Plethora was voted affirmatively; OI attended the meeting yesterday. Also excited about news on 3Legs!!</p>— jim mellon (@jimmhk) <a href="https://twitter.com/jimmhk/status/705380766662979584">3 March 2016</a></blockquote>
<script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>
 
http://www.marketwatch.com/story/go...s=1&utm_source=twitterfeed&utm_medium=twitter

MW-EG992_GLD_GC_20160302145602_NS.png


Gold prices produced a rare bullish “golden cross” technical pattern this week, the first of its kind in over 1 1/2 years, but it might be flashing more of a yellow light than green for gold bulls.

The 50-day moving average for gold futures GCJ6, +0.15% crossed above the 200-day moving average on Tuesday, a relatively rare technical event known as a “golden cross.” A golden cross also appeared in the SPDR Gold Trust exchange-traded fund’s GLD, +1.73% chart on Tuesday.

Many chart watchers believe this moving-average crossover marks the spot where a short-term rebound transitions into a longer-term trend.


FactSet
Gold bugs may be even more encouraged by the fact that the golden cross appeared after the 200-day moving average, which is used as a guide to the long-term trend, started turning higher, about three weeks ago.

There is only one problem--buying for the long term after a golden cross has failed more than it has succeeded. The last one that worked was seven years ago.

There have been five previous golden crosses in gold futures and the gold ETF over the past 10 years. Only the ones that appeared in December 2006 and February 2009 led to longer-term uptrends. The ones appearing in September 2012, March 2014 and July 2014 only led to very short-term rallies, followed by longer-term declines.

FactSet
Andrew Adams, market strategist at Raymond James, wrote in a note to clients that he doesn’t put a lot of emphasis on golden crosses, or the opposite death crosses, because he believes “they do a better job of telling investors what has already happened rather than what is going to happen.”

April gold futures gained 0.3% early Thursday, while the gold ETF tacked on 0.2% in premarket trade. They have both gained about 18% from their December closing lows, still a bit shy of the bull-market threshold of a 20% rally off a recent significant low.
 
ASA chart

big.chart

ASA interest picking up. With Gold so strong this could be due a big move.

It's cash costs at last figures were circa $900/oz so at $1270 they are making almost $400/oz cash margin on gold per oz and were at 70k oz p.a. production so potential cashflow of approaching $28m versus a current Mkt Cap of only £10m

3x cashflow would seem more realistic valuation so potential for a move to as high as £50m? or about 3p per share target ?
 
Last edited:
ASA on the up. Gold does look to be potentially breaking higher currently $1267 above the supposed technical resistance at $1263
 
ASA on the up. Gold does look to be potentially breaking higher currently $1267 above the supposed technical resistance at $1263

Nice few trading days for ASA,

With the MD bought 105mil @1p,

Looks strong to continue the up movement
 
Is the POO rise enough for investors ? Anything sub $60 still seems very low although some of the oil stocks so over-extended and marginal that they can turn on almost nothing right now it seems so will suit fast-money traders.
 
Is the POO rise enough for investors ? Anything sub $60 still seems very low although some of the oil stocks so over-extended and marginal that they can turn on almost nothing right now it seems so will suit fast-money traders.

Explorers have been so badly hit with POO that any movement upwards is causing huge fluctuations on no news.

Look at XEL and HUR over the last 2-3 days.
 
ASA facing technical resistance at 200 day MA

Classic case of price action disconnected to the real value of the business as gold price is higher today
 
ABZA another interesting company at Biotech Capital Conference. This 'Intel Inside' strategy could be a huge differentiator...

http://www.investegate.co.uk/abzena-plc--abza-/rns/business-update/201603090700094744R/

Licence portfolio progress

The portfolio of "Abzena inside" products has shown good progress with an additional Composite Human Antibody™ product being taken into clinical development by a US biotech company. It is currently being evaluated in a Phase I study in cancer patients. This takes the number of "Abzena inside" products at a clinical stage to eleven.

Another Composite Human Antibody™ being developed by a different US biotech partner completed a Phase Ia clinical study in healthy volunteers in which proof-of-mechanism was demonstrated. A Phase Ib study has now been initiated in patients with a range of rare diseases.

On 2 February 2016, Gilead Sciences, Inc. ('Gilead') announced that GS-5745, a Composite Human Antibody™, will go into Phase II clinical testing in both chronic obstructive pulmonary disease (COPD) and cystic fibrosis this year. Gilead previously announced that it would also start a Phase II study of GS-5745 in rheumatoid arthritis in 2016.

In the same announcement, Gilead also reiterated that Phase II studies with another Composite Human Antibody™, simtuzumab, were continuing in patients with non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) following a review by the data monitoring committee for these studies. They had previously announced that a Phase II study in patients with idiopathic pulmonary fibrosis (IPF) had been stopped.
 
TRX Tissue Regenix yet another interesting company from Biotech Capital Conference

http://www.investegate.co.uk/tissue...ranted-for-surgipuret-xd/201603090700094741R/

York, 9 March 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix") or ("The Group") the regenerative medical devices company, today announces that it has been granted 510k market clearance from the Food and Drug Administration ("FDA") for SurgiPure™ XD. This is the first FDA market clearance for a medical device developed by the Group and clears SurgiPure™ XD for a commercial launch within the US in 2016.

SurgiPure™ XD, a porcine dermis product which utilises the Group's patented dCELL® technology, will be used for the reinforcement of soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes, which may include the repair of hernias or body wall defects. The hernia market is estimated to have a $2-3bn global market value, with an estimated $1bn market opportunity in the US alone, with biologic treatments accounting for around $300m of this.
 
ASA facing technical resistance at 200 day MA

Classic case of price action disconnected to the real value of the business as gold price is higher today

Again today, took an hammering with not many trades
 
Some 'back of an envelope' calculations on ASA value suggest it could be as much as 10x undervalued

Screenshot_2016_03_10_at_11_08_25_AM.png
 
anyone recommend a good share dealing platform which has a decent android share dealing app.

Thanks
 
AGL presentation at Biotech Capital Conference

<iframe width="560" height="315" src="https://www.youtube.com/embed/C7UhtX2wrxI" frameborder="0" allowfullscreen></iframe>
 
ABZA presentation at Biotech Capital Conference

<iframe width="560" height="315" src="https://www.youtube.com/embed/KdveLjuJ-o8" frameborder="0" allowfullscreen></iframe>
 
CPX looking strong, taking a peek above 200 day MA line

Needs to break it on volume and news ideally
 
[MENTION=107620]s28[/MENTION], how do you resolve your capitalist leanings with your support for Mr Corbyn?
 
Corbyn has plenty of support amongst City Capitalists. If anything we know better than most how iniquitous it is that Society pays for Austerity caused by the 1%/Banksters.
 
Getting back to HNR above.

I asked a friend who has pro experience investing in mid/large cap North American Energy stocks to give his opinion on the above stock. There is not much to go on but he came back with some interesting perspectives. I tend to view small cap investing as a prospecting exercise where you try to uncover mispriced optionality and hope that 6/10 you are right and the occasional 1/10 which is right turns out to be mega right and makes up for most of the losers. It's quite a risk-seeking approach and probably only worthwhile for a small part of ones portfolio. My friend takes a more Institutional risk-averse approach consistent with proper Professional money managers who want to avoid any 'drawdowns' to capital. After all the first, second and third rules of investment are capital preservation.

Some of his comments below in italics :-

- "The North Dakota lease is likely worthless or worse - nothing is economic unless oil get back up to 60-70."

- "On the technology it's impossible to say. If it was genuinely good they would have bought it or go an exclusive, 50mm is nothing to them."

- "Refracking itself makes sense in an energy bull market when there is a scarcity of resource, now there's a huge inventory of wells that haven't even been fracked the first time. That doesn't mean to say the technology won't be valuable, it still will, but you have a time delay which is time for competition to develop I suppose so it adds to risk. "

- "Finally with regards to management ownership, high percentage of small market cap isn't that much skin - what is important is how much of their net worth is tied to it. If the ceo is worth big millions, it's not as impactful obviously as if he put his life savings in it."

- "there's so many unanswered questions though on the technology, management wealth, nature of SLB interest, evidence of technology being disruptive and working, milestones, competitive risk, what sort of fracked wells it works for - presumable not multiple well pad type wells?"
 
Getting back to HNR above.

I asked a friend who has pro experience investing in mid/large cap North American Energy stocks to give his opinion on the above stock. There is not much to go on but he came back with some interesting perspectives. I tend to view small cap investing as a prospecting exercise where you try to uncover mispriced optionality and hope that 6/10 you are right and the occasional 1/10 which is right turns out to be mega right and makes up for most of the losers. It's quite a risk-seeking approach and probably only worthwhile for a small part of ones portfolio. My friend takes a more Institutional risk-averse approach consistent with proper Professional money managers who want to avoid any 'drawdowns' to capital. After all the first, second and third rules of investment are capital preservation.

Some of his comments below in italics :-

- "The North Dakota lease is likely worthless or worse - nothing is economic unless oil get back up to 60-70."

- "On the technology it's impossible to say. If it was genuinely good they would have bought it or go an exclusive, 50mm is nothing to them."

- "Refracking itself makes sense in an energy bull market when there is a scarcity of resource, now there's a huge inventory of wells that haven't even been fracked the first time. That doesn't mean to say the technology won't be valuable, it still will, but you have a time delay which is time for competition to develop I suppose so it adds to risk. "

- "Finally with regards to management ownership, high percentage of small market cap isn't that much skin - what is important is how much of their net worth is tied to it. If the ceo is worth big millions, it's not as impactful obviously as if he put his life savings in it."

- "there's so many unanswered questions though on the technology, management wealth, nature of SLB interest, evidence of technology being disruptive and working, milestones, competitive risk, what sort of fracked wells it works for - presumable not multiple well pad type wells?"

This is the same guy who said 88E doesn't look like a goer? It's what 12 bagged since. Ok if he says so. Thanks anyway 👍
 
I've never mentioned 88E to him. 88E was a call I made on chart alone. Chart has played out. Never felt comfortable with the fundamentals and still don't.
 
You called 88E perfectly. Doc Holiday doesn't seem to like the fundamentals either. Just listened to his audio.
 
Back
Top